ENMD-2076 Receives Orphan Drug Designation for HCC

Share this content:
ENMD-2076 Receives Orphan Drug Designatino for HCC
ENMD-2076 Receives Orphan Drug Designatino for HCC

CASI Pharmaceuticals announced that the FDA has granted Orphan Drug designation to ENMD-2076 for the treatment of hepatocellular carcinoma (HCC).

ENMD-2076 is an orally-active, Aurora A/angiogenic kinase inhibitor shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase. ENMD-2076 also targets VEGFR, Flt-3, and FGFR 3 kinases.

ENMD-2076 has shown activity in Phase 1 clinical trials in solid tumor cancers including ovarian, breast, liver, renal, and sarcoma, as well as in leukemia and multiple myeloma. CASI is completing a Phase 2 trial of ENMD-2076 in ovarian cancer as well as a dual-institutional Phase 2 study of ENMD-2076 in triple-negative breast cancer, a Phase 2 study in advanced/metastatic soft tissue sarcoma, and a Phase 2 study in advanced ovarian clear cell carcinomas.

RELATED: Gastrointestinal Cancers Resource Center

ENMD-2076 has also received Orphan Drug designation for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.

For more information call (240) 864-2600 or visit Casipharmaceuticals.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs